These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23390452)

  • 61. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U; Lokeshwar N; Gupta S; Shirsath P
    Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acquired eyelash trichomegaly and generalized hypertrichosis associated with breast anomaly.
    Aghaei S; Dastgheib L
    Dermatol Online J; 2006 Feb; 12(2):19. PubMed ID: 16638412
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
    Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman D; Pao W; Riely GJ; Engelman JA; Kris MG; Jänne PA; Lynch T; Johnson BE; Miller VA
    J Clin Oncol; 2010 Jan; 28(2):357-60. PubMed ID: 19949011
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
    Fujiwara A; Yoshida M; Fujimoto H; Nakahara H; Ito K; Nishihama K; Yasuma T; Hataji O; Taguchi O; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
    Oncol Res; 2018 Aug; 26(7):1031-1036. PubMed ID: 29321093
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
    De Luca A; Normanno N
    Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer.
    Matos LV; Pissarra A; Malheiro M; Plácido AN
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31040141
    [No Abstract]   [Full Text] [Related]  

  • 77. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer.
    Takeda M; Nakagawa K
    Mol Clin Oncol; 2017 Jan; 6(1):3-6. PubMed ID: 28123721
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
    Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
    BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.